Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MONTREAL, Feb. 6, 2017 /CNW/ -- IntelGenx Technologies Corp. (OTCQX: IGXT), based in Montreal, focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform, today announced that the February 2nd presentation from Executive Vice President and CFO, Andre Godin is now available for on-demand viewing at VirtualInvestorConferences.com.
IntelGenx Technologies Corp.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- In December 2016 IntelGenX signed a definitive agreement with Chemo Group for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system)
- In December 2016 IntelGenx entered into a co-development and commercialization agreement with Endo for a new product utilizing IntelGenx' proprietary VersaFilm™ for the USA market
- In December 2016 IntelGenx signed an exclusive license agreement with Pharmatronic Co. for the commercialization of RIZAPORT® in the Republic of Korea (South Korea). RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines
- In November 2016 IntelGenx signed a binding term sheet for a license to Eli Lilly tadalafil erectile dysfunction dosing patent, United States Patent No. 6,943,166 (the '166 dosing patent)
Learn more about the event at www.VirtualInvestorConferences.com.
About IntelGenx Technologies Corp.
IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE IntelGenx Technologies Corp.
For further information: IntelGenx Corp. - Edward Miller, Director, IR and Corporate Communications, +1 514-331-7440 (ext. 217), email@example.com; VirtualInvestorConferences.com - Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org